Log in

NASDAQ:RYTMRhythm Pharmaceuticals Stock Price, Forecast & News

$18.39
+0.15 (+0.82 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.11
Now: $18.39
$18.73
50-Day Range
$18.39
MA: $21.21
$25.35
52-Week Range
$12.99
Now: $18.39
$25.86
Volume175,700 shs
Average Volume223,077 shs
Market Capitalization$811.35 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More
Rhythm Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RYTM
CUSIPN/A
Phone857-264-4280

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.40 per share

Profitability

Net Income$-140,730,000.00

Miscellaneous

Employees54
Market Cap$811.35 million
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$18.39
+0.15 (+0.82 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

How has Rhythm Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RYTM shares have increased by 22.6% and is now trading at $18.39.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Rhythm Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rhythm Pharmaceuticals
.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Rhythm Pharmaceuticals
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced its quarterly earnings data on Monday, August, 3rd. The company reported ($0.71) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.83) by $0.12.
View Rhythm Pharmaceuticals' earnings history
.

What price target have analysts set for RYTM?

7 equities research analysts have issued 1 year price targets for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $33.71 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals
.

Has Rhythm Pharmaceuticals been receiving favorable news coverage?

News articles about RYTM stock have trended positive recently, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Rhythm Pharmaceuticals
.

Are investors shorting Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,810,000 shares, an increase of 25.7% from the April 30th total of 1,440,000 shares. Based on an average daily trading volume, of 252,700 shares, the short-interest ratio is presently 7.2 days. Approximately 5.4% of the shares of the company are sold short.
View Rhythm Pharmaceuticals' Short Interest
.

Who are some of Rhythm Pharmaceuticals' key competitors?

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include Agile Therapeutics (AGRX), Amarin (AMRN), Exelixis (EXEL), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Nabriva Therapeutics (NBRV), Nektar Therapeutics (NKTR), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV) and Viking Therapeutics (VKTX).

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:
  • Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
  • Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
  • Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
  • Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
  • Mr. Simon D. Kelner, Chief HR Officer (Age 46)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include MPM Asset Management LLC (4.33%), Marshall Wace North America L.P. (0.68%), Bank of New York Mellon Corp (0.29%), Barclays PLC (0.23%), Bessemer Group Inc. (0.20%) and California Public Employees Retirement System (0.15%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan, Ra Capital Management, LP and Todd Foley.
View institutional ownership trends for Rhythm Pharmaceuticals
.

Which institutional investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, Goldman Sachs Group Inc., and Swiss National Bank. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, Ra Capital Management, LP, and Todd Foley.
View insider buying and selling activity for Rhythm Pharmaceuticals
.

Which institutional investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bessemer Group Inc., Athanor Capital LP, ProShare Advisors LLC, Bank of New York Mellon Corp, Marshall Wace LLP, Principal Financial Group Inc., and Matisse Capital.
View insider buying and selling activity for Rhythm Pharmaceuticals
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $18.39.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $811.35 million. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.